{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464384004
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[CD11]], [[CD18]]<ref name="jones">{{cite journal | last = Jones | first = R |date=April 2000 | title = Rovelizumab (ICOS Corp) | journal = [http://www.biomedcentral.com/idrugs/ IDrugs] | volume = 3 | issue = 4 | pages = 442&ndash;6 | pmid = 16100700}}</ref>
<!-- Clinical data -->
| tradename = LeukArrest
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 197099-66-4
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Rovelizumab''', also known as '''LeukArrest''' and '''Hu23F2G''', is a [[humanized monoclonal antibody]] which was an experimental [[immunosuppressive drug]]. Rovelizumab was developed by [[Icos]] to treat patients suffering from [[Shock (circulatory)|haemorrhagic shock]].<ref name="reed">{{cite news |first=Kristin |last=Reed |title=Icos Shares Skid After Drug Fails Test in Treating Shock |work=[[The Seattle Times]] |page=C7 |date=June 15, 1999 |accessdate=January 10, 2009 |url=http://community.seattletimes.nwsource.com/archive/?date=19990615&slug=2966656}}</ref> The drug is a monoclonal antibody that suppresses [[white blood cell]]s which become overly active during shock.<ref name="ervin">{{cite news |first=Keith |last=Ervin |title=Deep Pockets + Intense Research + Total Control = The Formulaâ€”Bothell Biotech Icos Keeps The Pipeline Full Of Promise |work=[[The Seattle Times]] |page=F1 |date=June 21, 1998 |accessdate=January 10, 2009 |url=http://community.seattletimes.nwsource.com/archive/?date=19980621&slug=2757327}}</ref><ref name="gorlick">{{cite news |first=Arthur |last=Gorlick |title=New 'Trauma Drug' is Saving Lives; Hope Comes For Severely Injured Patients |work=[[The Seattle Post-Intelligencer]] |page=C1 |date=August 29, 1997}}</ref> During testing the number of patients given the drug was low because rovelizumab had to be delivered within four hours of the injury and [[Informed consent|consent]] was required.<ref name="gorlick"/> Often the patient was unconscious and relatives had to be reached to give consent.<ref name="gorlick" /> In June&nbsp;1998, Icos and many medical centers asked the United States [[Food and Drug Administration]] (FDA) to waive consent requirements in situations where the patient was at high risk of dying and relatives could not be reached.<ref name="gorlick" /> While some medical ethicists opposed waiving consent, the FDA approved the proposal in August&nbsp;1998 for five medical centers.<ref>{{cite news |first=Maura |last=Lerner |title=HCMC Seeks Feedback On Plans To Test Trauma Drug; Doctors Hope to Test a Medicine That Could Save Lives of Patients Who Are Unable to Speak For Themselves |work=[[Star Tribune]] |page=1A |date=June 23, 1998}}</ref><ref>{{Cite web |url=http://www.fda.gov/ohrms/dockets/dockets/95s0158/95s-0158-rpt0003-01-vol10.pdf |title=Community consultation and public disclosure information for waiver of Informed Consent |accessdate=January 12, 2009 |publisher=[[Food and Drug Administration]] |date=August 27, 1998}}</ref> Development of rovelizumab was halted in April&nbsp;2000 when interim data from phase&nbsp;III clinical trials did not meet Icos's goals.<ref>{{cite news |title=Icos Halts Stroke-Drug Study After Late Results Disappoint |work=[[The Seattle Times]] |page=C6 |date=April 21, 2000 |accessdate=January 10, 2009 |url=http://community.seattletimes.nwsource.com/archive/?date=20000421&slug=4016638}}</ref> The company's goals for rovelizumab included reducing the chance of multiple organ failure and reducing the death-rate from shock at 28&nbsp;days.<ref name="reed" /> Rovelizumab was also being tested for treating [[heart attack]], [[multiple sclerosis]], and [[stroke]], and was being explored as a treatment for cerebral vasospasm, [[head trauma]], [[kidney transplantation]], and [[restenosis]].<ref name="jones" /><ref>{{cite news |title=Icos shares tumble on phase&nbsp;II results of LeukArrest |work=[http://www.reutershealth.com/ Reuters Health Medical News] |date=June 16, 1999}}</ref>

Multiple companies have tried to develop anti-[[CD18]] drugs, but none of them have been successful.<ref name="dove">{{cite journal |last=Dove |first=Alan |year=2000 |title=CD18 trials disappoint again  |journal=Nature Biotechnology |volume=18 |pages=817&ndash;8 |doi=10.1038/78412 |pmid=10932141 |issue=8}}</ref> Among them are [[Genentech]]'s [[erlizumab]], and two drugs developed by [[PDL BioPharma|Protein Design Labs]] and [[Centocor]].<ref name="dove" /> Although trials in humans have not gone well, the research of anti-CD18 drugs in animals has been encouraging.<ref name="dove" /> It is thought that the experimental medicines are affecting the lymphocyte adhesion pathway in humans in unintended ways.<ref name="dove" />

==References==
{{reflist}}

{{immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Monoclonal antibodies]]